ADAG

Adagene
ADAG
Market cap $102M

2.17 USD

-0.01

0.46%

At close Aug 8, 4:00 PM EDT

1 day

-0.46%

5 days

14.81%

1 month

14.81%

3 months

35.62%

6 months

27.65%

Year to date

5.34%

1 year

-12.15%

5 years

-92.76%

10 years

-92.76%

About: Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.

Employees: 138

Healthcare Biotechnology

0

Funds holding %

of 7,334 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

6.02% less ownership

Funds ownership: 18.92% [Q4 2024] → 12.9% (-6.02%) [Q1 2025]

13% less funds holding

Funds holding: 15 [Q4 2024] → 13 (-2) [Q1 2025]

43% less capital invested

Capital invested by funds: $20.3M [Q4 2024] → $11.6M (-$8.73M) [Q1 2025]

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

83% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 6

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$7

223%

upside

Avg. target

$7

223%

upside

High target

$7

223%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Leerink Partners

Daina Graybosch

223%upside

$7

Outperform

Initiated

6 Aug 2025

See Analyst Rankings

Financial journalist opinion

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA

- Alignment gained on Phase 2 inclusion/exclusion criteria, primary and secondary endpoints, and study design, including sample size and dosing regimen

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA

Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate

Adagene to provide proprietary antibody to ConjugateBio for development as novel bispecific ADCs SAN DIEGO and SUZHOU, China and PRINCETON, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a partnership with ConjugateBio Inc. (ConjugateBio) to provide a proprietary antibody for use in partner companies' bispecific ADC development programs.

Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate

Adagene announces up to $25 million strategic investment from Sanofi

- Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug

Adagene announces up to $25 million strategic investment from Sanofi

Adagene to Present at Jefferies Global Healthcare Conference 2025

SAN DIEGO and SUZHOU, China, May 27, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene's Chief Strategy Officer, Mickael Chane-Du, will participate in one-on-one investor meetings and a fireside chat at the Jefferies Global Healthcare Conference 2025, taking place June 3-5 in New York, New York.

Adagene to Present at Jefferies Global Healthcare Conference 2025

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

Adagene Appoints John Maraganore, Ph.D. as Executive Advisor

- Biotech luminary to mentor C-suite and provide strategic guidance - SAN DIEGO and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. John Maraganore as Executive Advisor. “Adagene is currently breaking a toxicity barrier with their proprietary masking technology, delivering a checkpoint inhibitor selectively and conditionally to tumor cells.

Adagene Appoints John Maraganore, Ph.D. as Executive Advisor

Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting

SAN DIEGO and SUZHOU, China, April 23, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at ASCO 2025 in Chicago, IL, May 30 - June 3.

Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update

Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial responses

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update

Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit

SAN DIEGO and SUZHOU, China, March 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its presentation at the 11th Annual Immuno-Oncology 360⁰ Summit in Boston on March 26, 2025. The summit, designed for all-size pharma/biotech companies, academia and investors seeking to enable a patient's immune system to eradicate cancer, provides the opportunity to hear directly from science and business stakeholders on the latest data impacting the field of immuno-oncology.

Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit

Adagene to Present at Leerink's Global Healthcare Conference 2025

SAN DIEGO and SUZHOU, China, March 06, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene's Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will participate in one-on-one investor meetings and provide a corporate update at Leerink's Global Healthcare Conference 2025, taking place March 10-12 in Miami, Florida.

Adagene to Present at Leerink's Global Healthcare Conference 2025

See News Rankings

Charts implemented using Lightweight Charts™